Loading…
Loading…
PYNKF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PYNKF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PYNKF and 80,000+ other tickers.
See exactly how PYNKF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PYNKF and 80,000+ other tickers.
Perimeter Medical Imaging AI, Inc., established in 2013 and headquartered in Toronto, Canada, is a medical technology innovator. The company focuses on creating and marketing sophisticated imaging solutions that empower surgeons, radiologists, and pathologists to meticulously examine microscopic tissue details throughout clinical interventions. A cornerstone of their offerings is an advanced Optical Coherence Tomography (OCT) imaging system, providing clinicians with precise cross-sectional views of tissue up to a depth of 2 millimeters. This comprehensive system incorporates the S-series…
Perimeter Medical Imaging AI, Inc. (PINK:CA) Q2 2026 Earnings Call Transcript
Results characterized by continued strong commercial momentum and improved operating performance Conference call/webcast today at 5:00 pm ET TORONTO and DALLAS, Aug. 20, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today reported preliminary financial results for its second quarter ended June 30, 2026, and provided a corporate update. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.
TORONTO and DALLAS, Aug. 13, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its second quarter 2026 financial and operating results after market close on Thursday, August 20, 2026. Following the announcement, Perimeter management will host a webcast and conference call to discuss the results and provide a corporate update.
Health system is first to commercially deploy Claire, the only FDA-approved, AI-enabled imaging device for margin assessment during breast-conserving surgery in the U.S. Claire is designed to enhance surgeons' ability to detect difficult-to-see cancer - far beyond what's visible to the naked eye - in real-time in the OR TORONTO and DALLAS, Aug. 13, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") (TSXV: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, today announced that Intermountain Health, the largest nonprofit health system in the Mountain West region, has become the first health system in the U.S. to commercially deploy Perimeter's Claire OCT System™, the only FDA-approved imaging device that uses AI during breast cancer surgery to help surgeons see microscopic tissue structures - where cancer can be difficult to detect - in real-time, for margin assessment. The stakes are significant: about one in five patients needs follow-up breast cancer surgeries because cancer wasn't detected in the operating room the first time.1 "Every breast surgeon wants to give their patient the best possible chance of completing treatment in a single surgery, but microscopic cancer can be difficult to identify in the operating room," said Dr. Teresa Reading, a breast surgeon at Intermountain Health LDS Hospital in Salt Lake City.
TORONTO and DALLAS, June 15, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present a Company update regarding current commercial strategy and discuss upcoming milestones at the Planet MicroCap Showcase on Wednesday, June 17, 2026 at 12:00 p.m. PDT (3:00 p.m.